Key result
Circulating microRNA-1 provided accurate early diagnosis of NSTEMI in patients with chronic kidney disease (AUC 0.879), with diagnostic accuracy comparable to non-CKD patients (84.3% vs 89.4%).
Why the study?
The early diagnosis of non-ST-segment elevation myocardial infarction in patients with chronic kidney disease remains a challenge.
Does circulating microRNA-1 provide better diagnostic accuracy than hs-cTnI for the early diagnosis of NSTEMI in patients with chronic kidney disease?
Observational (n=456)
Does circulating microRNA-1 provide better diagnostic accuracy than hs-cTnI for the early diagnosis of NSTEMI in patients with chronic kidney disease?
Circulating microRNA-1 may offer superior diagnostic accuracy and specificity compared to hs-cTnI for the early diagnosis of NSTEMI in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
microRNA-1 may aid early NSTEMI diagnosis in CKD; leaves open clinical adoption pending validation.
BACKGROUND: The early diagnosis of non-ST-segment elevation myocardial infarction (NSTEMI) in patients with chronic kidney disease (CKD) remains a challenge. METHODS: The study consecutively enrolled patients who had suffered from chest pain within 3 h whose electrocardiogram had no elevation in the ST segment. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, and the diagnostic criteria for NSTEMI were defined according to the recommended guideline. Circulating microRNA-1 was collected and determined by quantitative real-time reverse transcription polymerase chain reaction. RESULTS: A total of 456 patients with suspected NSTEMI were included. There were 115 patients in the CKD group, including 67 with NSTEMI, 20 with stable angina, 7 with unstable angina, 18 with heart failure, and 3 with other disorders. Compared with the NSTEMI group, the non-NSTEMI group just had significant differences in microRNA-1 and high-sensitivity cardiac troponin I (hs-cTnI) (both p < 0.05). The relative expression of microRNA-1 was significantly increased in the NSTEMI group as compared with that in the other disease groups (all p < 0.05). A receiver operating characteristic (ROC) curve analysis suggested that microRNA-1 and hs-cTnI had advantages in the early diagnosis of NSTEMI with CKD (AUC [area under the ROC curve] 0.879 and 0.812, respectively, both p < 0.05). Compared with that in the non-CKD group, the accuracy of microRNA-1 was almost as good in the CKD group (84.3 vs. 89.4%, p > 0.05). However, the diagnostic accuracy of hs-cTnI was significantly decreased (79.1 vs. 91.5%, p < 0.05), as was its specificity (75.0 vs. 95.5%, p < 0.05). There was no significant difference in the correlation between microRNA-1 and eGFR (p > 0.05), but a statistically significantly negative correlation between hs-cTnI and eGFR (p < 0.05). CONCLUSION: Circulating microRNA-1 is capable of early diagnosis of NSTEMI in patients with CKD suffering from chest pain.
No takes yet. Share an insight, caveat, or question.
Su et al. (2019) conducted an observational in Suspected NSTEMI (n=456). Circulating microRNA-1 vs. High-sensitivity cardiac troponin I (hs-cTnI) / non-CKD patients was evaluated on Early diagnosis of NSTEMI with CKD (AUC 0.879, p=< 0.05). Circulating microRNA-1 provided accurate early diagnosis of NSTEMI in patients with chronic kidney disease (AUC 0.879), with diagnostic accuracy comparable to non-CKD patients (84.3% vs 89.4%).
Synapse has enriched 10 related papers. Consider them for comparative context: